These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 12205536)

  • 21. Renal outcome and risk factors for end-stage renal disease in pediatric rapidly progressive glomerulonephritis.
    Piyaphanee N; Ananboontarick C; Supavekin S; Sumboonnanonda A
    Pediatr Int; 2017 Mar; 59(3):334-341. PubMed ID: 27542664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trends in incidence of treated end-stage renal disease, overall and by primary renal disease, in persons aged 20-64 years in Europe, Canada and the Asia-Pacific region, 1998-2002.
    Stewart JH; McCredie MR; Williams SM; Jager KJ; Trpeski L; McDonald SP;
    Nephrology (Carlton); 2007 Oct; 12(5):520-7. PubMed ID: 17803478
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Family history of end-stage renal disease among hemodialyzed patients in Poland.
    Gumprecht J; Zychma MJ; Moczulski DK; Gosek K; Grzeszczak W
    J Nephrol; 2003; 16(4):511-5. PubMed ID: 14696752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impaired control of plasma renin activity in hypertensive patients with end-stage renal disease due to chronic glomerulonephritis.
    Yasuda G; Nagasawa T; Umemura S; Shionoiri H; Ishii M
    Clin Nephrol; 1994 Nov; 42(5):300-8. PubMed ID: 7851031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathologic predictors of death and ESRD in patients with pauci-immune necrotizing glomerulonephritis.
    Kapitsinou PP; Ioannidis JP; Boletis JN; Sotsiou F; Nakopoulou L; Daphnis E; Moutsopoulos HM
    Am J Kidney Dis; 2003 Jan; 41(1):29-37. PubMed ID: 12500219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcomes for primary glomerulonephritis: New Zealand Glomerulonephritis Study.
    Chembo CL; Marshall MR; Williams LC; Walker RJ; Lynn KL; Irvine J; Pilmore HL
    Nephrology (Carlton); 2015 Dec; 20(12):899-907. PubMed ID: 26096749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mortality and renal outcome of primary glomerulonephritis in Korea: observation in 1,943 biopsied cases.
    Lee H; Kim DK; Oh KH; Joo KW; Kim YS; Chae DW; Kim S; Chin HJ
    Am J Nephrol; 2013; 37(1):74-83. PubMed ID: 23343855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypertension and renal insufficiency in children with chronic glomerulonephritis.
    Ito Y; Kinoshita S; Yoshimoto M; Shindou S; Yamashita F
    Int J Pediatr Nephrol; 1986; 7(4):187-90. PubMed ID: 3818177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hypertension and primary glomerulonephritis in adults. A study of 302 cases].
    Seba A; Rayane T; Kaci L; Haddoum F; Benabadji M
    Arch Mal Coeur Vaiss; 1997 Aug; 90(8):1181-4. PubMed ID: 9404432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians.
    Pavkov ME; Bennett PH; Knowler WC; Krakoff J; Sievers ML; Nelson RG
    JAMA; 2006 Jul; 296(4):421-6. PubMed ID: 16868300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. End-stage renal disease among silica-exposed gold miners. A new method for assessing incidence among epidemiologic cohorts.
    Calvert GM; Steenland K; Palu S
    JAMA; 1997 Apr; 277(15):1219-23. PubMed ID: 9103346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension.
    Sim JJ; Bhandari SK; Shi J; Reynolds K; Calhoun DA; Kalantar-Zadeh K; Jacobsen SJ
    Kidney Int; 2015 Sep; 88(3):622-32. PubMed ID: 25945406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recurrent Glomerulonephritis in Renal Transplantation: Experience in Our Renal Transplantation Center.
    Cañas L; López D; Pérez JF; Bancu I; Juega J; Ariza A; Bonet J; Lauzurica R
    Transplant Proc; 2015 Oct; 47(8):2354-6. PubMed ID: 26518925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence of end-stage renal disease in overseas-born, compared with Australian-born, non-indigenous Australians.
    Stewart JH; McCredie MR; McDonald SP
    Nephrology (Carlton); 2004 Aug; 9(4):247-52. PubMed ID: 15363057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials.
    Thomopoulos C; Parati G; Zanchetti A
    J Hypertens; 2017 May; 35(5):922-944. PubMed ID: 28141660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinico-pathological characteristics and outcomes of patients with biopsy-proven hypertensive nephrosclerosis: a retrospective cohort study.
    Liang S; Le W; Liang D; Chen H; Xu F; Chen H; Liu Z; Zeng C
    BMC Nephrol; 2016 Apr; 17():42. PubMed ID: 27066888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An improved understanding of the causes of end-stage renal disease.
    Young EW
    Semin Nephrol; 1997 May; 17(3):170-5. PubMed ID: 9165646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A population-based, prospective study of blood pressure and risk for end-stage renal disease in China.
    Reynolds K; Gu D; Muntner P; Kusek JW; Chen J; Wu X; Duan X; Chen CS; Klag MJ; Whelton PK; He J
    J Am Soc Nephrol; 2007 Jun; 18(6):1928-35. PubMed ID: 17475822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease.
    Tsui JI; Vittinghoff E; Shlipak MG; Bertenthal D; Inadomi J; Rodriguez RA; O'Hare AM
    Arch Intern Med; 2007 Jun; 167(12):1271-6. PubMed ID: 17592100
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.